PT3536324T - 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 - Google Patents

4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Info

Publication number
PT3536324T
PT3536324T PT191520360T PT19152036T PT3536324T PT 3536324 T PT3536324 T PT 3536324T PT 191520360 T PT191520360 T PT 191520360T PT 19152036 T PT19152036 T PT 19152036T PT 3536324 T PT3536324 T PT 3536324T
Authority
PT
Portugal
Prior art keywords
gpr139
benzotriazines
modulators
dihydro
oxo
Prior art date
Application number
PT191520360T
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3536324T publication Critical patent/PT3536324T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
PT191520360T 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 PT3536324T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
PT3536324T true PT3536324T (pt) 2021-11-10

Family

ID=55022667

Family Applications (2)

Application Number Title Priority Date Filing Date
PT15816275T PT3221298T (pt) 2014-11-20 2015-11-19 Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139
PT191520360T PT3536324T (pt) 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT15816275T PT3221298T (pt) 2014-11-20 2015-11-19 Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (pt)
EP (2) EP3221298B1 (pt)
JP (2) JP6637501B2 (pt)
KR (1) KR102582021B1 (pt)
CN (2) CN107108531B (pt)
AU (1) AU2015349866B2 (pt)
BR (1) BR112017010311A2 (pt)
CA (1) CA2968242C (pt)
CL (1) CL2017001292A1 (pt)
CO (1) CO2017005959A2 (pt)
CR (1) CR20170275A (pt)
CY (2) CY1122613T1 (pt)
DK (2) DK3536324T3 (pt)
DO (1) DOP2017000120A (pt)
EA (1) EA033728B1 (pt)
EC (1) ECSP17038999A (pt)
ES (2) ES2897545T3 (pt)
GE (1) GEP20196961B (pt)
HR (2) HRP20212009T1 (pt)
HU (2) HUE044145T2 (pt)
IL (1) IL252311B (pt)
JO (1) JO3719B1 (pt)
LT (2) LT3221298T (pt)
MA (1) MA40993B1 (pt)
MD (1) MD3221298T2 (pt)
MX (1) MX2017006448A (pt)
MY (1) MY187423A (pt)
NZ (1) NZ732208A (pt)
PE (1) PE20170899A1 (pt)
PH (1) PH12017500920B1 (pt)
PL (2) PL3221298T3 (pt)
PT (2) PT3221298T (pt)
RS (2) RS59078B1 (pt)
SG (1) SG11201704002UA (pt)
SI (2) SI3221298T1 (pt)
TN (1) TN2017000196A1 (pt)
TW (1) TWI684590B (pt)
UA (1) UA120375C2 (pt)
UY (1) UY36406A (pt)
WO (1) WO2016081736A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
CA3121108A1 (en) * 2018-10-16 2020-04-23 The Scripps Research Institute Methods related to opioid therapeutics
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
TW202124386A (zh) 2019-09-16 2021-07-01 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
JP2023524133A (ja) * 2020-05-08 2023-06-08 武田薬品工業株式会社 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
JP2023541485A (ja) 2020-09-21 2023-10-02 武田薬品工業株式会社 統合失調症のための処置
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
WO1987004928A1 (en) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
EP0315390B1 (en) * 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
CA2533824A1 (en) 2003-07-31 2005-02-10 Irm, Llc Bicyclic compounds and compositions as pdf inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
KR101115891B1 (ko) * 2007-03-23 2012-02-13 에프. 호프만-라 로슈 아게 아자-피리도피리미딘온 유도체
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
US20140336216A1 (en) 2013-03-14 2014-11-13 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
CY1124929T1 (el) 2023-01-05
EA033728B1 (ru) 2019-11-20
CN112062730A (zh) 2020-12-11
AU2015349866A1 (en) 2017-06-15
ES2734735T3 (es) 2019-12-11
US20170348319A1 (en) 2017-12-07
JP2017535559A (ja) 2017-11-30
UY36406A (es) 2016-06-30
CL2017001292A1 (es) 2018-02-16
HUE057451T2 (hu) 2022-05-28
HRP20191003T1 (hr) 2019-08-23
US20190070187A1 (en) 2019-03-07
MA40993A (fr) 2017-09-27
HRP20212009T1 (hr) 2022-04-01
US11173161B2 (en) 2021-11-16
PT3221298T (pt) 2019-06-28
PE20170899A1 (es) 2017-07-12
EP3536324B1 (en) 2021-10-06
MA40993B1 (fr) 2019-07-31
DK3536324T3 (da) 2021-10-25
LT3536324T (lt) 2021-12-10
KR20170084324A (ko) 2017-07-19
UA120375C2 (uk) 2019-11-25
CO2017005959A2 (es) 2017-10-20
PL3536324T3 (pl) 2022-02-07
US20160145218A1 (en) 2016-05-26
TW201625566A (zh) 2016-07-16
PH12017500920A1 (en) 2017-11-20
US10561662B2 (en) 2020-02-18
CA2968242A1 (en) 2016-05-26
EA201791096A1 (ru) 2017-11-30
JP6918088B2 (ja) 2021-08-11
WO2016081736A1 (en) 2016-05-26
DOP2017000120A (es) 2017-06-15
MD3221298T2 (ro) 2019-10-31
MY187423A (en) 2021-09-22
TN2017000196A1 (en) 2018-10-19
SG11201704002UA (en) 2017-06-29
JO3719B1 (ar) 2021-01-31
CA2968242C (en) 2022-11-08
KR102582021B1 (ko) 2023-09-22
CN112062730B (zh) 2023-09-29
EP3221298A1 (en) 2017-09-27
CN107108531A (zh) 2017-08-29
US9556130B2 (en) 2017-01-31
TWI684590B (zh) 2020-02-11
AU2015349866B2 (en) 2020-12-03
EP3536324A1 (en) 2019-09-11
CN107108531B (zh) 2020-10-20
ECSP17038999A (es) 2017-10-31
IL252311B (en) 2020-07-30
US20170095480A1 (en) 2017-04-06
EP3221298B1 (en) 2019-04-03
SI3221298T1 (sl) 2019-10-30
RS59078B1 (sr) 2019-09-30
JP2020063285A (ja) 2020-04-23
JP6637501B2 (ja) 2020-01-29
BR112017010311A2 (pt) 2017-12-26
RS62563B1 (sr) 2021-12-31
GEP20196961B (en) 2019-03-25
ES2897545T3 (es) 2022-03-01
LT3221298T (lt) 2019-08-12
PH12017500920B1 (en) 2017-11-20
SI3536324T1 (sl) 2021-12-31
IL252311A0 (en) 2017-07-31
US10159677B2 (en) 2018-12-25
PL3221298T3 (pl) 2019-10-31
US9770450B2 (en) 2017-09-26
MX2017006448A (es) 2017-09-12
NZ732208A (en) 2023-02-24
CY1122613T1 (el) 2021-05-05
HUE044145T2 (hu) 2019-09-30
CR20170275A (es) 2017-10-30
DK3221298T3 (da) 2019-06-24
US20200129518A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
HK1245634A1 (zh) 作為egfr調節劑的取代的2-苯胺基嘧啶衍生物
IL249643A0 (en) Eye preparation
IL252311B (en) 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
EP3153153A4 (en) Hair-dye composition
IL251976A0 (en) Phage therapy
EP3153154A4 (en) Hair-dye composition
HK1226054A1 (zh) 作為mglur4調節劑的乙炔基咪唑烷 2，4 二酮衍生物
IL248783A0 (en) Fluorescence quenching compounds, preparations containing them and their uses
HRP20180920T1 (hr) Mješoviti travnjak
EP3187551A4 (en) Anthocyanin-based pigment composition
SI3220893T1 (sl) Sestavek na osnovi COQ10
GB201403017D0 (en) Composition
GB201403561D0 (en) Composition
ZA201703701B (en) Ophthalmic composition
EP3188649A4 (en) Polygraph
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
GB201402487D0 (en) Composition
AU2014900322A0 (en) Direct Reduction
GB201401510D0 (en) Composition